Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort
暂无分享,去创建一个
Ben Murrell | Jianming Tang | Adam Godzik | Pham Phung | Terri Wrin | Pascal Poignard | William Kilembe | Jill Gilmour | A. Godzik | A. Kamali | T. Wrin | E. Karita | P. Poignard | S. Allen | B. Murrell | L. Bekker | S. Crotty | O. Anzala | Xiayu Huang | J. Gilmour | E. Sanders | C. Havenar-Daughton | E. Landais | Shane Crotty | Linda-Gail Bekker | Anatoli Kamali | M. Simek | P. Phung | A. Ramos | Mubiana Inambao | Jianming Tang | W. Kilembe | S. Lakhi | Elise Landais | Melissa Simek | Eduard J. Sanders | M. Inambao | Susan Allen | Alejandra Ramos | M. Price | Colin Havenar-Daughton | Etienne Karita | Xiayu Huang | Matt A. Price | Lalinda Wickramasinghe | Charoan B. Bian | Shabir Lakhi | Omu Anzala | Vinodh Edward | Sergei L. Kosakovsky-Pond | V. Edward | Lalinda Wickramasinghe | C. B. Bian
[1] J. Mascola,et al. Biochemically Defined HIV-1 Envelope Glycoprotein Variant Immunogens Display Differential Binding and Neutralizing Specificities to the CD4-binding Site* , 2011, The Journal of Biological Chemistry.
[2] David Nemazee,et al. Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.
[3] T. Kepler,et al. Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors , 2011, Journal of Virology.
[4] B. Korber,et al. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection , 2014, AIDS.
[5] B. Haynes,et al. HIV‐1 neutralizing antibodies: understanding nature's pathways , 2013, Immunological reviews.
[6] Chaim A. Schramm,et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.
[7] Anne Piantadosi,et al. Chronic HIV-1 Infection Frequently Fails to Protect against Superinfection , 2007, PLoS pathogens.
[8] A. Fauci,et al. Ending AIDS--is an HIV vaccine necessary? , 2014, The New England journal of medicine.
[9] Dennis R. Burton,et al. Variable Loop Glycan Dependency of the Broad and Potent HIV-1-Neutralizing Antibodies PG9 and PG16 , 2010, Journal of Virology.
[10] R. Wyatt,et al. Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. , 2015, Cell reports.
[11] J. D. de Jong,et al. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV‐seropositive individuals in relation to the number of CD4+ lymphocytes , 1994, AIDS.
[12] L. Morris,et al. Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop , 2011, Journal of Virology.
[13] Lynn Morris,et al. Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape , 2012, Nature Medicine.
[14] Richard T. Wyatt,et al. Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables , 2009, Journal of Virology.
[15] A. Barone,et al. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. , 2005, Vaccine.
[16] J. Overbaugh,et al. Early development of broad neutralizing antibodies in HIV-1 infected infants , 2014, Nature Medicine.
[17] M. Altfeld,et al. Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 , 2011, PLoS pathogens.
[18] Alessandro Sette,et al. Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. , 2013, Immunity.
[19] Lynn Morris,et al. Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C , 2008, Journal of Virology.
[20] H. Schuitemaker,et al. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression , 2009, AIDS.
[21] John R Mascola,et al. Antibody responses to envelope glycoproteins in HIV-1 infection , 2015, Nature Immunology.
[22] Ron Diskin,et al. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.
[23] Lynn Morris,et al. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein , 2012, The Journal of experimental medicine.
[24] B. Haynes,et al. Host Controls of HIV Neutralizing Antibodies , 2014, Science.
[25] Mario Roederer,et al. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.
[26] G. Learn,et al. Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. , 2013, Virology.
[27] Yan Liu,et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120 , 2013, Nature Structural &Molecular Biology.
[28] Mark Connors,et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies , 2007, Nature Medicine.
[29] D. Burton,et al. Two Classes of Broadly Neutralizing Antibodies within a Single Lineage Directed to the High-Mannose Patch of HIV Envelope , 2014, Journal of Virology.
[30] D. Burton,et al. Antibody 2G12 Recognizes Di-Mannose Equivalently in Domain- and Nondomain-Exchanged Forms but Only Binds the HIV-1 Glycan Shield if Domain Exchanged , 2010, Journal of Virology.
[31] Xiping Wei,et al. Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.
[32] M. Carrington,et al. Association of HLA-DRB1-restricted CD4+ T cell responses with HIV immune control , 2013, Nature Medicine.
[33] H. Schuitemaker,et al. Longitudinal Analysis of Early HIV-1-Specific Neutralizing Activity in an Elite Neutralizer and in Five Patients Who Developed Cross-Reactive Neutralizing Activity , 2011, Journal of Virology.
[34] C. Gray,et al. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. , 2007, Virology.
[35] Lynn Morris,et al. Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection , 2009, PLoS pathogens.
[36] E. Bunnik,et al. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. , 2010, The Journal of infectious diseases.
[37] B. Haynes,et al. The Development of CD4 Binding Site Antibodies during HIV-1 Infection , 2012, Journal of Virology.
[38] M. Altfeld,et al. Early Preservation of CXCR5+ PD-1+ Helper T Cells and B Cell Activation Predict the Breadth of Neutralizing Antibody Responses in Chronic HIV-1 Infection , 2014, Journal of Virology.
[39] B. Walker,et al. Identifying HLA-Associated Polymorphisms in HIV-1 , 2016 .
[40] Feng Gao,et al. Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals , 2011, Journal of Virology.
[41] Han Gao,et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. , 2014, Cell reports.
[42] C. A. Derdeyn,et al. B-Lymphocyte Dysfunction in Chronic HIV-1 Infection Does Not Prevent Cross-Clade Neutralization Breadth , 2012, Journal of Virology.
[43] D. Montefiori,et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. , 1999, Science.
[44] Hui Li,et al. Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection , 2007, Journal of Virology.
[45] L. Morris,et al. The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection , 2011, Journal of Virology.
[46] Jessica L. Prince,et al. Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression , 2015, Proceedings of the National Academy of Sciences.
[47] Stephen J O'Brien,et al. The influence of HLA genotype on AIDS. , 2003, Annual review of medicine.
[48] Jaap Heringa,et al. HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity , 2013, Retrovirology.
[49] Gwo-Yu Chuang,et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-120 interface , 2014, Nature.
[50] M. Mulligan,et al. Polymorphisms in HLA Class I Genes Associated with both Favorable Prognosis of Human Immunodeficiency Virus (HIV) Type 1 Infection and Positive Cytotoxic T-Lymphocyte Responses to ALVAC-HIV Recombinant Canarypox Vaccines , 2001, Journal of Virology.
[51] A. Kamali,et al. Disease progression by infecting HIV-1 subtype in a seroconverter cohort in sub-Saharan Africa , 2013, AIDS.
[52] Pham Phung,et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.
[53] Barton F. Haynes,et al. High-Mannose Glycan-Dependent Epitopes Are Frequently Targeted in Broad Neutralizing Antibody Responses during Human Immunodeficiency Virus Type 1 Infection , 2011, Journal of Virology.
[54] A. Kamali,et al. Host genetics and viral load in primary HIV-1 infection: clear evidence for gene by sex interactions , 2014, Human Genetics.
[55] Lynn Morris,et al. Broad Neutralization of Human Immunodeficiency Virus Type 1 Mediated by Plasma Antibodies against the gp41 Membrane Proximal External Region , 2009, Journal of Virology.
[56] Pham Phung,et al. Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.
[57] M. Carrington,et al. Immunogenetics of spontaneous control of HIV. , 2012, Annual review of medicine.
[58] Adam Godzik,et al. A Blueprint for HIV Vaccine Discovery. , 2012, Cell host & microbe.
[59] J. Baeten,et al. Breadth of Neutralizing Antibody Response to Human Immunodeficiency Virus Type 1 Is Affected by Factors Early in Infection but Does Not Influence Disease Progression , 2009, Journal of Virology.
[60] A. Kamali,et al. Dynamics of viremia in primary HIV-1 infection in Africans: insights from analyses of host and viral correlates. , 2014, Virology.
[61] J. Mascola,et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.
[62] Sebastian Bonhoeffer,et al. Virulence and Pathogenesis of HIV-1 Infection: An Evolutionary Perspective , 2014, Science.
[63] J. Moore,et al. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1 , 1997, Journal of virology.
[64] A. Lapedes,et al. Antigenicity and Immunogenicity of Transmitted/Founder, Consensus, and Chronic Envelope Glycoproteins of Human Immunodeficiency Virus Type 1 , 2013, Journal of Virology.
[65] P. Goepfert,et al. Cumulative Impact of Host and Viral Factors on HIV-1 Viral-Load Control during Early Infection , 2012, Journal of Virology.
[66] Holly Janes,et al. Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies , 2009, Journal of Virology.
[67] Terri Wrin,et al. Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm , 2009, Journal of Virology.
[68] William R. Schief,et al. Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV , 2014, Science Translational Medicine.
[69] D. Burton,et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo , 2012, Proceedings of the National Academy of Sciences.
[70] David Heckerman,et al. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients , 2008, The Journal of experimental medicine.
[71] T. Kepler,et al. Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design , 2012, Journal of Virology.
[72] Feng Gao,et al. Phenotypic properties of transmitted founder HIV-1 , 2013, Proceedings of the National Academy of Sciences.
[73] Wayne C Koff,et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. , 2014, Immunity.
[74] John P. Moore,et al. A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies , 2013, PLoS pathogens.
[75] Baoshan Zhang,et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.
[76] Chaim A. Schramm,et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies , 2014, Nature.
[77] L. Morris,et al. Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes , 2013, PLoS pathogens.
[78] Feng Gao,et al. Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies , 2014, Cell.
[79] G. Shaw,et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection , 1994, Journal of virology.
[80] J. Mascola,et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques , 2014, The Journal of experimental medicine.
[81] Pascal Poignard,et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques , 2009, Nature Medicine.
[82] E. Hunter,et al. Viral characteristics of transmitted HIV , 2008, Current opinion in HIV and AIDS.
[83] Xuesong Yu,et al. Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.
[84] M. Nussenzweig,et al. Memory B Cell Antibodies to HIV-1 gp140 Cloned from Individuals Infected with Clade A and B Viruses , 2011, PloS one.
[85] L. Morris,et al. Virological features associated with the development of broadly neutralizing antibodies to HIV-1. , 2015, Trends in microbiology.
[86] Dennis R. Burton,et al. A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals , 2010, PLoS pathogens.